Royal Bank Of Canada Reiterates "Outperform" Rating for Concordia Healthcare Corp (CXR)

Royal Bank Of Canada's price objective would indicate a potential upside of 274.22% from the company's current price.

Concordia International Corp. on 9/30/2016 reported its EPS as $1.38 with the analysts projecting the EPS of the stock as $1.39.

10/16/2015 - Concordia Healthcare Corp. had its "buy" rating reiterated by analysts at S&P Capital IQ. The stock of Concordia International Corp (NASDAQ: CXRX) has "Buy" rating given on Tuesday, August 11 by Canaccord Genuity. TD Securities reissued a "hold" rating and set a $14.00 target price (down previously from $20.00) on shares of Concordia Healthcare Corp.in a report on Wednesday, August 17th. Finally, RBC Capital Markets reiterated an "outperform" rating and set a $38.00 target price (up from $33.00) on shares of Concordia Healthcare Corp.in a research note on Sunday, September 4th. Goldman Sachs initiated it with "Neutral" rating and $32 target price in Monday, June 6 report. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the stock. Concordia Healthcare Corp has a 12 month low of $4.52 and a 12 month high of $58.75.

Concordia International Corp. (NASDAQ:CXRX) has its dividend (annual) of 0 while its Dividend Yield (annual) is 0%. About 644,498 shares traded hands. The Average Volume Traded by the company in the last trading session is at 1.38 Million. The stock has a 50-day moving an average price of $7.46 and a 200-day moving average price of $23.54.

The Company got Downgrade by CIBC on 15-Aug-16 from Sector Perform to Sector Underperform. (NASDAQ: CXRX) last released its earnings results on Friday, August 12th. The company beat the analyst EPS Estimate with the difference of $-0.01. The firm earned $231.70 million during the quarter, compared to analyst estimates of $229.76 million. After $1.21 actual earnings per share reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.

Analysts are also projecting an Average Revenue Estimate for Concordia International Corp.as $208.12 Million in the Current Quarter.

Institutional investors have recently made changes to their positions in the company. ProShare Advisors LLC raised its position in shares of Concordia Healthcare Corp.by 0.6% in the second quarter. ProShare Advisors LLC now owns 37,975 shares of the company's stock valued at $818,000 after buying an additional 224 shares during the last quarter.

12/03/2015 - Concordia Healthcare Corp. had its "hold" rating reiterated by analysts at Mackie. Citigroup Inc. now owns 8,976 shares of the company's stock valued at $184,000 after buying an additional 1,401 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Concordia Healthcare Corp.by 12.4% in the first quarter. Nomura Holdings Inc. raised its position in shares of Concordia Healthcare Corp.by 1,183.4% in the second quarter. After trading began at $3.66, the stock was seen striking at $3.72 as its peak price and $3.55 as its lowest price. PNC Financial Services Group Inc. acquired a new position in shares of Concordia Healthcare Corp. during the second quarter valued at $1,855,000. These price targets are a consensus analysis of 8 brokers.

Several large investors have recently bought and sold shares of the company.

  • Zachary Reyes